Innate Immunity and Colonic Inflammation: Enhanced Expression of Epithelial α-Defensins

Jan Wehkamp(Robert Bosch Hospital), Klaus Fellermann(Apple (Israel)), M. Duchrow, Eduard F. Stange(John Radcliffe Hospital), Bettina Schwind(University Gastroenterology), K. J. Schmidt(University Hospital Schleswig-Holstein), Klaus Herrlinger(Robert Bosch Hospital), Steffi Baxmann(University Gastroenterology), Alfred C. Feller, Charlotte Wohlschläger(University of Lübeck)
Digestive Diseases and Sciences
June 1, 2002
10.1023/a:1015334917273
Cited by 82

Related Papers

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613